FDA warned Proquimes S.A. that its active pharmaceutical ingredient manufacturing violated current good manufacturing practice (CGMP) because process, equipment, and cleaning validation were missing.
What happened
FDA reviewed records Proquimes submitted after FDA's April 16, 2020 request under section 704(a)(4) and later communication. The company said it had not performed process validation, equipment qualification, or cleaning validation for a USP API (an API meeting the U.S. Pharmacopeia standard) it distributed to the United States, and it did not test each incoming component lot for identity. FDA placed all drugs made by the firm on Import Alert 66-40, which can stop U.S. imports, on December 3, 2020.
What FDA found
The company did not validate its manufacturing process, so it could not show the process consistently makes API meeting quality attributes.
FD&C Act section 501(a)(2)(B)The company did not qualify critical manufacturing equipment and called the equipment "unqualified."
FD&C Act section 501(a)(2)(B)The company did not validate cleaning procedures for shared API equipment, risking cross-contamination.
FD&C Act section 501(a)(2)(B)The company did not test each incoming production material lot for identity, citing lack of resources.
FD&C Act section 501(a)(2)(B)
What FDA wants
FDA tells Proquimes to respond in writing within 15 working days with corrective actions for all cited deviations and a schedule if it cannot meet that deadline. FDA also recommends a qualified CGMP consultant and says the import alert can remain until the firm resolves the issues and FDA confirms compliance.
Who should pay attention
- drugmakers buying API from Proquimes
- brands with products using API from this site
- supplier quality teams tracking Import Alert 66-40
This is a summary. Read the original letter on fda.gov.